Compared with cyclophosphamide, the efficacy and safety of tofacitinib in the treatment of active IgG4-related diseases were evaluated.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Disease remission rate at 1 month, 3 months and 6 months of treatment (%)
Timeframe: 1 month, 3 months and 6 months of treatment